Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
GSK wins FDA approval for neladalkib lung cancer drug from Nuvalent deal
00

GSK wins FDA approval for neladalkib lung cancer drug from Nuvalent deal

Nov 17, 2026

On November 17, 2026, the U.S. FDA granted accelerated approval to GSK's oral lung cancer drug Nelkarmi (neladalkib) for patients with advanced ALK-positive non-small cell lung cancer. Acquired through GSK's $10.6 billion buyout of Nuvalent, Nelkarmi is the UK drugmaker's second approved lung cancer treatment from the deal. Under CEO Luke Miels, GSK aims to rebuild its oncology portfolio to achieve £40 billion in annual revenue by 2031 and offset upcoming HIV patent expirations.

FDA approval details for Nelkarmi

  • ▪Accelerated approval for GSK's Nelkarmi was based on clinical trial data showing anti-cancer activity and tumor shrinkage, including in patients whose cancer had spread to the brain
  • ▪FDA granted accelerated approval to GSK's oral therapy neladalkib for ALK-positive non-small cell lung cancer after ALK tyrosine kinase inhibitors

Acquisition background and financial strategy

  • ▪CEO Luke Miels said GSK acquired Nuvalent in part to help offset expected revenue losses from HIV medicines containing dolutegravir going off-patent starting in 2028
  • ▪Prior to buying Nuvalent for $10.6 billion, GSK expanded its oncology portfolio through acquisitions including Tesaro for $5.1 billion in 2018 and Sierra Oncology for $1.9 billion in 2022
  • ▪Nelkarmi is GSK's second commercial lung cancer drug acquired from its $10.6 billion acquisition of Nuvalent, following the July 2026 FDA approval of Jideytro

Competitive landscape and clinical trials

  • ▪GSK is evaluating neladalkib directly against Roche's Alecensa in a late-stage clinical trial to assess its potential efficacy as a first-line lung cancer treatment
  • ▪GSK's Nelkarmi will compete against established ALK-targeted lung cancer treatments including Roche's Alecensa and Pfizer's Lorbrena

Lung cancer demographics

  • ▪GSK Chief Scientific Officer Tony Wood stated that patients suffering from ALK-positive lung cancer are often young and can remain on medication for years
  • ▪According to the American Cancer Society, approximately 229,410 people in the United States are expected to be diagnosed with lung cancer in 2026

GSK oncology goals and revenue projections

  • ▪Analysts surveyed by Bloomberg estimate that GSK's Nelkarmi could generate approximately $1 billion in annual sales by 2032
  • ▪Jefferies analysts estimated that the lung cancer drug pipeline acquired by GSK from Nuvalent could yield between $5 billion and $7 billion in peak sales
  • ▪Oncology products accounted for 6 percent of GSK's £33 billion in total revenues in 2025

4 sources

Reuters
US FDA approves GSK's second lung cancer drug from historic Nuvalent deal | Reuters
View source article
Bloomberg
GSK Wins US Approval for Nelkarmi Lung Cancer Drug After Nuvalent Acquisition
View source article
Financial Times
GSK wins approval for second lung cancer drug from $10.6bn Nuvalent deal
View source article
Endpoints
GSK’s Nuvalent buyout delivers again as FDA clears Nelkarmi for lung cancer
View source article

Story comments

Loading comments…

Related entities

United StatesPfizer

Related Projects

BloombergGSKAmerican Cancer SocietyRoche

Topics

Pharmaceutical IndustryCancer treatmentFDA drug approvalCancer and Cancer TreatmentAccelerated approval pathwaysDrug Policy, Pricing & ApprovalMergers & acquisitions (M&A)Cancer & OncologyMergers and acquisitionsTargeted cancer therapy